3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
23
Kidney Neoplasms
7
Carcinoma, Hepatocellular
7
Osteosarcoma
5
Sarcoma, Ewing
4
Neoplasm Metastasis
4
Sarcoma
3
Clear-cell metastatic renal cell carcinoma
3
Recurrence
2
Prostatic Neoplasms
2
Neuroendocrine Tumors
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Adrenocortical Carcinoma
2
von Hippel-Lindau Disease
1
Wilms Tumor
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Urachal adenocarcinoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Interventions
lutetium Lu 177 dotatate
3
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
zimberelimab
1
pasireotide
1
cabozantinib
1
amino-acid, glucose, and electrolyte solution
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Somatostatin
1
Radiosurgery
1
Everolimus
1
Disulfides
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled